AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-a

a6269o

FORM 6-K


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , Washington , Iskra Reic , Ghady Haidar , Adrian Kemp , Meerausw Immunocompromise , Health Database Study , Securities Exchange , Company On Social Media Astrazeneca , University Of Pittsburgh Medical Center , Large United States Commercial Insurance Health Plan , Nasdaq , Forum Infect Dis , Investor Relations Team , Astrazeneca , Commission File Number , Company Secretary , Lancet Regional Health , Foreign Issuer , Securities Exchange Act , File Number , Crick Avenue , Regulationst Rule , Pittsburgh Medical Center , Executive Vice President , Immune Therapies , Rare Diseases , Social Media , Immunocompromised Populations , Omicron Era , Observational Population Based , Increased Risk , Immunocompromised Individuals Despite Receipt , Retrospective Health Database Study , Multiple Sclerosis Are , High Risk , Death Despite High Rates , Oral Presentation , Immunocompromising Conditions Among Patients , Severe Acute Respiratory Infection , Test Negative Case Control , Post Hoc Analysis , Curr Med Res , Neutralizes Historical , Emerging Variants , Being Developed , Open Forum Infect ,